Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

41
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
41
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

22
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
22
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

680
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
680
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

27
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

18
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
18

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac dysfunction during immune checkpoint inhibitor therapy: association with extracardiac immune-related adverse events.

Cardio-oncology (London, England)·2026
Same author

Refining the treatment of immune checkpoint inhibitor-associated myocarditis: Challenges, innovations and rechallenge considerations.

British journal of pharmacology·2026
Same author

Early timepoint <sup>99m</sup>Tc-DPD whole body scintigraphy and quantitative SPECT/CT imaging for diagnosis of cardiac ATTR amyloidosis.

EJNMMI research·2026
Same author

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum.

British journal of pharmacology·2026
Same author

Semi-quantitative evaluation of early phase <sup>99m</sup>Tc-DPD scintigraphy in patients with suspected cardiac amyloidosis.

Annals of nuclear medicine·2026
Same author

Transthyretin stabilizer therapy increases naturally-occurring antibodies in ATTR cardiomyopathy.

Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis·2026

Related Experiment Video

Updated: Aug 21, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

4.7K

[Drug-induced cardiomyopathies].

Lars Michel, Tienush Rassaf

    Deutsche Medizinische Wochenschrift (1946)
    |November 17, 2022
    PubMed
    Summary

    Cardiotoxic drug side effects impact cancer patient survival. This review covers diagnosing and treating cardiovascular complications from chemotherapy, immunotherapy, and blood transfusions.

    Area of Science:

    • Cardiology
    • Oncology
    • Pharmacology

    Context:

    • Rising cancer survival rates increase patient exposure to cardiotoxic therapies.
    • Cardiovascular complications significantly impact patient morbidity and mortality.
    • Understanding drug-induced cardiac issues is crucial for effective management.

    Purpose:

    • To provide an overview of cardiotoxic substances and their cardiovascular side effects.
    • To summarize diagnostic and therapeutic principles for drug-induced cardiotoxicity.
    • To highlight complications from anthracyclines, immunotherapy, and transfusion-related hemochromatosis.

    Summary:

    • This article reviews cardiovascular side effects of classic and modern cancer therapies, including anthracyclines and immunotherapy.
    • It details diagnostic and therapeutic strategies for managing cardiotoxicity.

    More Related Videos

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    9.9K
    Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
    12:46

    Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

    Published on: August 17, 2022

    2.6K

    Related Experiment Videos

    Last Updated: Aug 21, 2025

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    4.7K
    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
    08:09

    A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

    Published on: June 7, 2018

    9.9K
    Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
    12:46

    Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

    Published on: August 17, 2022

    2.6K
  • Cardiac involvement in transfusion-related hemochromatosis is also discussed.

    • Impact:

    • Improved knowledge of cardiotoxic effects enhances patient management and outcomes.
    • Early diagnosis and treatment of cardiovascular complications are vital for cancer patients.
    • This review aids oncologists and cardiologists in addressing therapy-related cardiac issues.